title: HIV patients with psychiatric disorders are less likely to discontinue HAART.
abstract: OBJECTIVE
  We examined whether having a psychiatric disorder among HIV-infected individuals is associated with differential rates of discontinuation of HAART and whether the number of mental health visits impact these rates.
  
  
  METHODS
  This longitudinal study (fiscal year: 2000-2005) used discrete time survival analysis to evaluate time to discontinuation of HAART. The predictor variable was presence of a psychiatric diagnosis (serious mental illness versus depressive disorders versus none).
  
  
  METHODS
  Five United States outpatient HIV sites affiliated with the HIV Research Network.
  
  
  METHODS
  The sample consisted of 4989 patients. The majority was nonwhite (74.0%) and men (71.3%); 24.8% were diagnosed with a depressive disorder, and 9% were diagnosed with serious mental illness.
  
  
  METHODS
  Time to discontinuation of HAART adjusting for demographic factors, injection drug use history, and nadir CD4 cell count.
  
  
  RESULTS
  Relative to those with no psychiatric disorders, the hazard probability for discontinuation of HAART was significantly lower in the first and second years among those with SMI [adjusted odds ratio: first year, 0.57 (0.47-0.69); second year, 0.68 (0.52-0.89)] and in the first year among those with depressive disorders [adjusted odds ratio: first year, 0.61 (0.54-0.69)]. The hazard probabilities did not significantly differ among diagnostic groups in subsequent years. Among those with psychiatric diagnoses, those with six or more mental health visits in a year were significantly less likely to discontinue HAART compared with patients with no mental health visits.
  
  
  CONCLUSIONS
  Individuals with psychiatric disorders were significantly less likely to discontinue HAART in the first and second years of treatment. Mental health visits are associated with decreased risk of discontinuing HAART.
authors.affiliation: Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21212, USA. shimelho@psych.umaryland.edu
authors.forename: Seth
authors.initials: S
authors.lastname: Himelhoch
authors.forename: Clayton H
authors.initials: CH
authors.lastname: Brown
authors.forename: James
authors.initials: J
authors.lastname: Walkup
authors.forename: Geetanjali
authors.initials: G
authors.lastname: Chander
authors.forename: P Todd
authors.initials: PT
authors.lastname: Korthius
authors.forename: Joseph
authors.initials: J
authors.lastname: Afful
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Gebo
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000523:psychology*; D003866:Depressive Disorder / Q000150:complications / Q000523:psychology; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications* / Q000523:psychology; D008605:Mental Health Services / Q000706:statistics & numerical data; D008875:Middle Aged; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data; D010349:Patient Compliance / Q000523:psychology; D010352:Patient Dropouts / Q000523:psychology*; D012189:Retrospective Studies